Key Points
- Stabilize ABCs; begin targeted evaluation without delaying life-saving therapy.
- Use system-specific risk tools to guide testing and disposition.
- Order high-yield tests first; escalate imaging when indicated.
- Start evidence-based initial therapy and reassess frequently.
Algorithm
- Primary survey and vitals; IV access and monitors.
- Focused history/physical; identify red flags and likely etiologies.
- Order system-appropriate labs and imaging (see Investigations).
- Initiate guideline-based empiric therapy (see Pharmacology).
- Reassess response; arrange consultation and definitive management.
Clinical Synopsis & Reasoning
Asthma exacerbations reflect acute airway inflammation and bronchoconstriction triggered by infection, allergens, or irritants. Assess severity via work of breathing, PEF/FEV₁, and gas exchange; identify risk factors for near‑fatal events (prior intubation, repeated ED visits). Distinguish from COPD, anaphylaxis, or PE when atypical features are present.
Treatment Strategy & Disposition
Administer repeated SABA (± SAMA) nebulizations, systemic corticosteroids early, and controlled oxygen to achieve target saturations. Consider IV magnesium for severe attacks and non‑invasive ventilation in impending fatigue; intubate if refractory with attention to dynamic hyperinflation. Discharge when PEF ≥70% predicted and stable, ensuring inhaled corticosteroid‑containing regimen and action plan; admit for persistent hypoxemia, rising CO₂, or poor response.
Epidemiology / Risk Factors
- Risk factors vary by condition and patient profile
Investigations
| Test | Role / Rationale | Typical Findings | Notes |
|---|---|---|---|
| CBC | Baseline hematology | Abnormal counts | |
| BMP | Electrolytes/renal | Derangements |
Discharge Criteria
| Criterion | Target |
|---|---|
| Sustained improvement after treatments | Yes |
| Oxygen saturation adequate on room air | Yes |
| Access to inhaler and spacer plus plan | Yes |
Pharmacology
| Medication | Mechanism | Onset | Role in Therapy | Limitations |
|---|---|---|---|---|
| Ipratropium (neb) | M3 antagonism | Minutes | Adjunct bronchodilation (moderate-severe) | Dry mouth; ED use; pediatric dosing/contra nuances |
| Albuterol (neb) | β2-agonist | Minutes | Bronchodilation rescue | Tachycardia tremor; ED use; pediatric dosing/contra nuances |
| Systemic corticosteroid | Glucocorticoid receptor | Hours | Reduce airway inflammation | Hyperglycemia, mood changes; ED use; pediatric dosing/contra nuances |
| Magnesium sulfate (IV) | Ca²⁺ antagonism (bronchodilation) | Minutes | Severe exacerbation refractory | Hypotension; ED use; pediatric dosing/contra nuances |
| Epinephrine (IM) | α/β agonist | Minutes | Impending respiratory failure/anaphylaxis overlap | Arrhythmia; ED use; pediatric dosing/contra nuances |
Prognosis / Complications
- Prognosis depends on severity, comorbidities, and timeliness of care
Patient Education / Counseling
- Explain red flags and when to seek emergent care.
- Reinforce medication adherence and follow-up plan.
Notes
Provide asthma action plan and inhaler technique teaching. Arrange timely primary care or pulmonology follow up.
References
Use the Library, QBank, CCS, and analytics in one study workflow.
You just reviewed Pediatric Asthma Exacerbation - ED Management. MDSteps helps you turn that review into exam-style practice, missed-item flashcards, and a readiness dashboard that shows what to study next.
- 16,000+ USMLE-style questions across Step 1, Step 2, and Step 3
- CCS simulator with timed orders, live vitals, and case feedback
- Depth-on-Demand™ explanations and Anki-exportable flashcards
- Library + QBank + analytics for $27/month or $299 lifetime